Шаблоны LeoTheme для Joomla.
GavickPro Joomla шаблоны

April 2015  

Volume 1 Issue 2 

 _____________________________________________________________________________________________________________

Research Article

Orthotopic Ileal Neobladder Construction Using Non-Absorbable Staples: Is It Safe?

Rafael Siqueira Rocha Vidal*, Alexandre Stievano Carlos, Daniel de Oliveira Gomes, Bruno Hurtado Rodrigues, Ronnie Muniz Oliveira

Approximately 30% of bladder cancer patients present with muscle-invasive disease at the time of diagnosis and the standard treatment is radical cystectomy. The challenge for surgeons has been selecting an ideal urinary diversion technique for these patients. The main objective of this paper is to evaluate the post-surgical complications, resulting from the use of non-absorbable titanium staples in Orthotopic Ileal Neobladder (OIN) construction.                                                                           

                                                                                                                                 Download PDF Full text   __________________________________________________________________________________________________

Research Article

18F-Fluorodeoxyglucose versus 18F-Fluoromethylcholine Positron Emission Tomography in The Detection of Ductal Carcinoma in situ of The Breast

Kerryn Butler-Henderson*, Nat P Lenzo, Nelson K Loh, Roger I Price, Andy H Lee

Poor sensitivity and accuracy have been reported using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the detection of ductal carcinoma in situ (DCIS), yet no reference to the use of 18F-fluoromethylcholine (FCH) PET can be identified in the in situ breast cancer literature. This study determined the tumour to background ratio for cases where both FDG and FCH-PET were used to detect DCIS.                                                                          

                                                                                                                                 Download PDF Full text   __________________________________________________________________________________________________

Review Article

Cancer-Related Fatigue and Its Management

Timothy Allen, MD, Ph.D*, Giridhar M.N.V, MD,MBA, Ghazaleh Shoja E Razavi MD

Fatigue is the most common symptom found in the cancer patients, with a prevalence of more than 60%, as reported in the major part of various studies. This paper mainly reviews the management of the cancer related fatigue. In this paper, various pharmacologic agents are discussed for the management of fatigue in cancer patients and these agents comprises of psychostimulants, anti-depressants, corticosteroids, and hematopoietic. There are some other therapeutic agents such as paroxetine (serotonin reuptake inhibitors), bupropion, modafinil, and l-carnitine, but these agents are less studied for cancer related fatigue and at present, these agents are focusing on different clinical trials.                                                                          

                                                                                                                                 Download PDF Full text   __________________________________________________________________________________________________

Review Article
Mechanisms of Resistance to Rituximab in B-cell Lymphoma

Timothy Allen, MD, Ph.D*, Giridhar M.N.V, MD,MBA, Ghazaleh Shoja E Razavi MD

Rituximab or Anti-CD20, is a chimeric monoclonal antibody (MoAb)that has become a ubiquitous component for improved therapeutic options for patients with B-cell non-Hodgkin lymphoma (B-NHL)and other known hematological malignancies. The MoAbs has the direct antiproliferative effect on the B cells in vitro. This review article focuses on the mechanism of resistance to the Rituximab(anti CD-20)mediated cytotoxicity.Understanding of the complexity of mechanism facilitates the progressof pharmacological strategies to reduce resistance.                                                                    

                                                                                                                                 Download PDF Full text  __________________________________________________________________________________________________

Review Article

Immunotherapy in Metastatic Renal Cell Carcinoma

Timothy Allen, MD, Ph.D*, Giridhar M.N.V, MD,MBA, Ghazaleh Shoja E Razavi MD

Immunotherapy plays a crucial role in the treatment of patients with renal cell carcinoma. Metastatic renal cell carcinoma (MRCC) remains a therapeutic challenge because of its strong resistance to both chemotherapy and radiation therapy. This review explains the advancements of new biologics for the treatment of metastasized renal cell carcinoma with the use of cytokines, interleukin – 2 (IL-2), lymphocyte killer cells (LKC), and IFN alpha.                                                                

                                                                                                                                 Download PDF Full text

Contact Us:
9600 GREAT HILLS
TRAIL # 150 W
AUSTIN, TEXAS
78759 ( TRAVIS COUNTY)
E-mail : info@jacobspublishers.com
Phone : 512-400-0398